I would like to thank Dr. Bach for his contributions over the last few years in establishing the foundation for our clinical organization and working closely with Dr. Coll as part of this planned transition." About Blai Coll, M.D., Ph.D. Dr. Coll is a physician-scientist with 15 years of experience in clinical development. Prior to being promoted to Chief Medical Officer, Dr. Coll was Vice President of Endocrine and Metabolism Clinical Development at Structure Therapeutics, where he led the company's clinical development activities for GSBR-1290. Before joining Structure, Dr. Coll was at Amgen where he held different leadership positions in the cardiovascular group, including management of lifecycle studies for Repatha ® (open label extension studies with more than 6,000 patients) and early development projects in the cardiovascular space.